A
Anji Pharmaceuticals
Clinical-stage biopharmaceutical company developing delayed-release metformin for type 2 diabetes patients with chronic kidney disease
About Anji Pharmaceuticals
Anji Pharma (Anji Pharmaceuticals) was a clinical-stage global medicines company founded in 2018 in Cambridge, Massachusetts, focused on developing late-stage therapies for high-prevalence metabolic and gastrointestinal conditions. The company operated a hub-and-spoke model that insourced core clinical, regulatory and manufacturing capabilities while working with partners such as the drug development business of Labcorp and, later, Population Health Partners.
Its lead program, ANJ900, a delayed-release formulation of metformin, was studied in a multinational Phase 3 program (DREAM-T2D) to enable safe glucose management in patients with type 2 diabetes and moderate chronic kidney disease, with a second Phase 3 program (DREAM-CKD) planned for more advanced disease. A second program, ANJ908 (pradigastat), was in development for chronic idiopathic constipation. Anji also advanced an oncology program, the MCL1 inhibitor TTX-810, through its subsidiary Trueline Therapeutics.
Anji was incubated and backed by Viva BioInnovator and raised a $70M Series B in September 2021 led by Xiamen Changrong Investment Management. The company wound down and reported closing in August 2024.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 42.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| FundingOther financing | Jan 2024 | $0 | — | Viva BioInnovator | ↗ |
| SERIES BOther financing | Sep 2021 | $70M | $280M | Xiamen Changrong Investment Management | — |
Growth signals
Latest recorded traffic for Anji Pharmaceuticals is 830 monthly website visits, up 1560% over the last three months. Anji Pharmaceuticals's team grew 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Viva Ventures Biotech Fund
JMCR Partners
Series A1 investor entered at this stage
- XMXiamen Changrong Investment Management
Other known investors1 additional known investor
- VBViva BioInnovator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anji Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anji Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.